KWF grant on PDAC phosphoproteomics awarded
- Post by: OPL
- January 19, 2017
- Comments off
Interrogating the phosphoproteome for targets and markers in pancreatic cancer
Pancreatic cancer (PDAC) is a highly lethal and chemoresistant disease. The failure of (targeted) therapies can be attributed to the strong inter- and intra-tumor heterogeneity in terms of complexity of genetic aberrations and the resulting signaling pathway activities, as well as to resistance mechanisms that quickly adapt the tumor to drugs.
Together this complexity calls for a global post-genomic read-out of aberrant biochemical signaling in clinically relevant models to improve treatment response and outcome of patients with PDAC. We aim to employ phosphoproteomics to understand aberrant signaling and mechanisms underlying drug resistance in PDAC, and we will explore new drug targets and treatment strategies.